DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
PF-04958242 is an investigational drug.
There have been 14 clinical trials for PF-04958242. The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Schizophrenia, Cognition Disorders, and Deafness. The leading clinical trial sponsors are Pfizer, Biogen, and Yale University.
There are thirty-eight US patents protecting this investigational drug and three hundred and sixty-six international patents.
Recent Clinical Trials for PF-04958242
|Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants||Biogen||Phase 1|
|A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)||Biogen||Phase 2|
|A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)||Pfizer||Phase 2|
Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PF-04958242||Start Trial||2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides||Pfizer Inc. (New York, NY)||Start Trial|
|PF-04958242||Start Trial||Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors||Pfizer Inc. (New York, NY)||Start Trial|
|PF-04958242||Start Trial||Imidazopyridazine compounds||Pfizer Inc. (New York, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|